Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227065 | 1.00 | TLR9 (0.60) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL567172 | 0.90 | NFE2L2 (0.64) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL567173 | 0.90 | NFE2L2 (0.64) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL2980565 | 0.90 | CYP19A1 (0.74) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL2980561 | 0.90 | CYP19A1 (0.74) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 | |
| SCHEMBL28460574 | 0.85 | CYP19A1 (0.76) | TLR9CYP19A1NFE2L2MAPTFBP1 | |
| SCHEMBL28460573 | 0.85 | CYP19A1 (0.76) | TLR9CYP19A1NFE2L2MAPTFBP1 | |
| SCHEMBL11745232 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP1A1CYP1A2CYP1B1MAPT | |
| SCHEMBL11745227 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP1A1CYP1A2CYP1B1MAPT | |
| SCHEMBL14046248 | 0.85 | CYP19A1 (0.64) | TLR9CYP19A1NFE2L2CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | TLR9 3841/4885CYP19A1 22/4885NFE2L2 386/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | TLR9 4437/4885CYP19A1 146/4885NFE2L2 430/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | TLR9 3919/4885CYP19A1 20/4885NFE2L2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.